B

y acquiring Juno Therapeutics (JUNO) for $9 billion, Celgene (CELG) is making a bullish bet on genetically engineered cells known as CAR-Ts becoming a cornerstone of cancer treatment. The same strategic reasoning compelled Gilead Sciences (GILD) to purchase Kite Pharma for $11 billion last year.

There are no guarantees these bets will pay off. Currently, two CAR-T therapies, including Kite’s Yescarta, are approved to treat a relatively small set of blood cancer patients who have run out of other medical options. The early commercial launches of these CAR-Ts have been slowed by their high cost and the complexities of manufacturing and reimbursement.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.